Drug Patents owned by Cmp Dev Llc
1. List of Atorvaliq drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11369567 | CMP DEV LLC | Aqueous suspension suitable for oral administration |
Jun, 2037
(14 years from now) | |
Drugs and Companies using ATORVASTATIN CALCIUM ingredient
Market Authorisation Date: 01 February, 2023
Treatment: NA
Dosage: SUSPENSION;ORAL
2. List of Carospir drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11395828 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(13 years from now) | |
| US11491166 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(13 years from now) | |
| US10888570 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(13 years from now) | |
| US10660907 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(13 years from now) | |
| US10624906 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(13 years from now) | |
| US9757394 | CMP DEV LLC | Spironolactone aqueous formulations |
Oct, 2036
(13 years from now) | |
| US10493083 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(13 years from now) | |
| US11389461 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(13 years from now) | |
Drugs and Companies using SPIRONOLACTONE ingredient
Market Authorisation Date: 04 August, 2017
Treatment: Carospir is indicated for treatment of nyha class iii-iv heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure; C...
Dosage: SUSPENSION;ORAL
CAROSPIR family patents
12
United States
1
Morocco
1
Canada
1
European Union
3. List of Norliqva drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11458095 | CMP DEV LLC | NA |
Feb, 2041
(17 years from now) | |
| US11253474 | CMP DEV LLC | Pharmaceutical solution of amlodipine |
Feb, 2041
(17 years from now) | |
Drugs and Companies using AMLODIPINE BESYLATE ingredient
Market Authorisation Date: 24 February, 2022
Treatment: Norliqva is indicated for the treatment of hypertension, to lower blood pressure in adults and children 6 years of age and older; Norliqva is indicated for the symptomatic treatment of chronic stable ...
Dosage: SOLUTION;ORAL
NORLIQVA family patents
4
United States
4. List of Potassium Phosphates drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10632150 | CMP DEV LLC | Potassium phosphates composition for injection |
Apr, 2039
(16 years from now) | |
Drugs and Companies using POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC ingredient
Market Authorisation Date: 19 September, 2019
Treatment: Potassium phosphates injection is indicated as a source of phosphorus in intravenous fluids to correct hypophosphatemia in adults and pediatric patients 12 years of age and older
Dosage: SOLUTION;INTRAVENOUS
5. List of Tadliq drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11382917 | CMP DEV LLC | Liquid oral formulations for tadalafil |
Dec, 2038
(15 years from now) | |
Drugs and Companies using TADALAFIL ingredient
Market Authorisation Date: 17 June, 2022
Treatment: Tadliq is indicated for the treatment of pulmonary arterial hypertension (pah) (who group 1) to improve exercise ability
Dosage: SUSPENSION;ORAL
TADLIQ family patents
6
United States
2
India
1
Singapore
1
Brazil
1
Morocco
1
Japan
1
IB
1
Canada
1
Australia
1
China
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic